-
Ultragenyx Discontinues Phase 3 GNE Myopathy Study
Wednesday, August 23, 2017 - 11:22am | 391Read More...Shares of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) tumbled more than 12 percent Wednesday after the company offered a disappointing update concerning a muscle-disease drug study. The biopharmaceutical company, which focuses on the development of novel products for rare and ultra-rare diseases,...
-
Ultragenyx Pharmaceutical Spikes 4% Following Release Of Positive Phase 2 Data
Thursday, April 21, 2016 - 12:28pm | 238Read More...Shares of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) gained more than 4 percent on Thursday after company reported positive interim data from a Phase 2 study. Ultragenyx Pharmaceutical focuses on the development of novel products for rare and ultra-rare diseases. The company announced that...
